vimarsana.com
Home
Live Updates
Denali Therapeutics Announces Completion of Enrollment for R
Denali Therapeutics Announces Completion of Enrollment for R
Denali Therapeutics Announces Completion of Enrollment for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial
SOUTH SAN FRANCISCO, Calif., May 01, 2024 -- Denali Therapeutics Inc. , a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier ...
Related Keywords
Massachusetts ,
United States ,
Sabrina Paganoni ,
Laura Hansen ,
Suma Babu ,
Seanm Healey ,
Department Of Neurology ,
Nasdaq ,
Denali Therapeutics Inc ,
Exchange Commission ,
Merit Cudkowicz ,
Julieanne Dorn Professor ,
Harvard Medical ,
Chief Medical Officer ,
Massachusetts General Hospital ,
South San ,
Private Securities Litigation Reform Act ,
Chief Medical ,
Quarterly Reports ,
Media Contact ,
Investor Relations ,